The economic burden of dementia in low- and middle-income countries (LMICs): a systematic review.


Journal

BMJ global health
ISSN: 2059-7908
Titre abrégé: BMJ Glob Health
Pays: England
ID NLM: 101685275

Informations de publication

Date de publication:
04 2022
Historique:
received: 13 09 2021
accepted: 08 02 2022
entrez: 5 4 2022
pubmed: 6 4 2022
medline: 7 4 2022
Statut: ppublish

Résumé

More than two-thirds of people with dementia live in low- and middle-income countries (LMICs), resulting in a significant economic burden in these settings. In this systematic review, we consolidate the existing evidence on the cost of dementia in LMICs. Six databases were searched for original research reporting on the costs associated with all-cause dementia or its subtypes in LMICs. The national-level dementia costs inflated to 2019 were expressed as percentages of each country's gross domestic product (GDP) and summarised as the total mean percentage of GDP. The risk of bias of studies was assessed using the Larg and Moss method. We identified 14 095 articles, of which 24 studies met the eligibility criteria. Most studies had a low risk of bias. Of the 138 LMICs, data were available from 122 countries. The total annual absolute per capita cost ranged from US$590.78 for mild dementia to US$25 510.66 for severe dementia. Costs increased with the severity of dementia and the number of comorbidities. The estimated annual total national costs of dementia ranged from US$1.04 million in Vanuatu to US$195 billion in China. The average total national expenditure on dementia estimated as a proportion of GDP in LMICs was 0.45%. Indirect costs, on average, accounted for 58% of the total cost of dementia, while direct costs contributed 42%. Lack of nationally representative samples, variation in cost components, and quantification of indirect cost were the major methodological challenges identified in the existing studies. The estimated costs of dementia in LMICs are lower than in high-income countries. Indirect costs contribute the most to the LMIC cost. Early detection of dementia and management of comorbidities is essential for reducing costs. The current costs are likely to be an underestimation due to limited dementia costing studies conducted in LMICs, especially in countries defined as low- income. The protocol was registered in the International Prospective Register of Systematic Reviews database with registration number CRD42020191321.

Identifiants

pubmed: 35379735
pii: bmjgh-2021-007409
doi: 10.1136/bmjgh-2021-007409
pmc: PMC8981345
pii:
doi:

Types de publication

Journal Article Systematic Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Department of Health
Pays : United Kingdom

Informations de copyright

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Pharmacoeconomics. 2009;27(5):391-403
pubmed: 19586077
Acta Psychiatr Scand. 2010 Apr;121(4):243-59
pubmed: 19694634
Value Health. 2019 Sep;22(9):1026-1032
pubmed: 31511179
Int J Geriatr Psychiatry. 2004 Feb;19(2):170-7
pubmed: 14758582
Pharmacoeconomics. 2011 Aug;29(8):653-71
pubmed: 21604822
Int J Geriatr Psychiatry. 1997 Aug;12(8):841-56
pubmed: 9283930
Alzheimers Dement. 2007 Apr;3(2):81-91
pubmed: 19595921
Arch Neurol. 1993 Jun;50(6):643-50
pubmed: 8503802
Dement Geriatr Cogn Disord. 2006;21(3):175-81
pubmed: 16401889
PLoS One. 2018 Mar 1;13(3):e0193209
pubmed: 29494693
J Nutr Health Aging. 2010 Oct;14(8):655-63
pubmed: 20922342
Expert Rev Pharmacoecon Outcomes Res. 2013 Oct;13(5):663-73
pubmed: 24138651
J Alzheimers Dis. 2008 Sep;15(1):109-15
pubmed: 18780971
J Nutr Health Aging. 2010 Oct;14(8):648-54
pubmed: 20922341
EBioMedicine. 2015 Dec 22;4:184-90
pubmed: 26981556
Gerontologist. 2003 Apr;43(2):158-64
pubmed: 12677073
Lancet Neurol. 2008 Sep;7(9):812-26
pubmed: 18667359
Alzheimers Dement. 2015 Aug;11(8):946-54
pubmed: 25614127
Alzheimers Dement. 2010 Mar;6(2):98-103
pubmed: 20298969
Int J Geriatr Psychiatry. 1998 Nov;13(11):755-66
pubmed: 9850872
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
J Am Med Dir Assoc. 2018 Mar;19(3):200-206.e1
pubmed: 29306605
Alzheimer Dis Assoc Disord. 2001 Jan-Mar;15(1):56-7
pubmed: 11236826
Health Econ Rev. 2012 Sep 11;2(1):18
pubmed: 22963680
Pharmacy (Basel). 2019 Sep 24;7(4):
pubmed: 31554156
Alzheimers Dement. 2018 Apr;14(4):483-491
pubmed: 29433981
Alzheimers Dement. 2017 Jan;13(1):1-7
pubmed: 27583652
Indian J Public Health. 2013 Apr-Jun;57(2):71-7
pubmed: 23873192
Dement Neuropsychol. 2015 Jan-Mar;9(1):32-41
pubmed: 29213939
PLoS One. 2017 Mar 7;12(3):e0172204
pubmed: 28267795
Dement Geriatr Cogn Disord. 2003;15(1):34-43
pubmed: 12457077
Value Health. 2019 Oct;22(10):1137-1145
pubmed: 31563256
Int Psychogeriatr. 2017 Nov;29(11):1835-1840
pubmed: 28592351
N Engl J Med. 2013 Apr 4;368(14):1326-34
pubmed: 23550670
Expert Rev Pharmacoecon Outcomes Res. 2017 Apr;17(2):189-202
pubmed: 28351177
Alzheimers Dement. 2017 Jul;13(7):801-809
pubmed: 28161279
Int J Geriatr Psychiatry. 2020 Nov;35(11):1376-1384
pubmed: 32662184
Int J Geriatr Psychiatry. 2015 Feb;30(2):111-29
pubmed: 25320002
Appl Health Econ Health Policy. 2018 Feb;16(1):15-29
pubmed: 28856585
Bull World Health Organ. 2017 Jan 01;95(1):18-26
pubmed: 28053361
Int Psychogeriatr. 2011 May;23(4):554-61
pubmed: 21044400
J Alzheimers Dis. 2019;69(3):795-806
pubmed: 31156170
Int J Equity Health. 2018 Mar 22;17(1):37
pubmed: 29566721
Int J Geriatr Psychiatry. 2005 Jul;20(7):616-22
pubmed: 16021668
Curr Neurol Neurosci Rep. 2012 Oct;12(5):511-9
pubmed: 22864986
Alzheimers Res Ther. 2016 Nov 18;8(1):59
pubmed: 27986093
Am J Alzheimers Dis Other Demen. 2011 Jun;26(4):298-309
pubmed: 21561991
J Am Geriatr Soc. 2004 Feb;52(2):187-94
pubmed: 14728626
Curr Opin Psychiatry. 2019 Sep;32(5):461-464
pubmed: 31082844
Neurology. 2018 Mar 13;90(11):e993-e994
pubmed: 29530970
Int Psychogeriatr. 2007 Aug;19(4):705-18
pubmed: 16870037
Iran J Neurol. 2019 Jan 5;18(1):7-12
pubmed: 31316730
Alzheimers Dement. 2013 Jan;9(1):1-11.e3
pubmed: 23305821

Auteurs

Siti Maisarah Mattap (SM)

Global Public Health, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia.

Devi Mohan (D)

Global Public Health, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia devi.mohan@monash.edu.

Andrea Mary McGrattan (AM)

School of Biomedical, Nutritional and Sports Sciences, Newcastle University, Newcastle upon Tyne, UK.

Pascale Allotey (P)

Global Public Health, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia.
United Nations University International Institute for Global Health, Bandar Tun Razak, Wilayah Persekutuan Kuala Lumpur, Malaysia.

Blossom Cm Stephan (BC)

Institute of Mental Health, University of Nottingham, Nottingham, UK.

Daniel D Reidpath (DD)

International Centre for Diarrhoeal Disease Research Bangladesh, Dhaka, Bangladesh.
Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia.

Mario Siervo (M)

School of Life Sciences, University of Nottingham, Nottingham, UK.

Louise Robinson (L)

Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.

Nathorn Chaiyakunapruk (N)

Department of Pharmacotherapy, The University of Utah College of Pharmacy, Salt Lake City, Utah, USA.
School of Pharmacy, Monash University Malaysia, Selangor, Malaysia.
IDEAS Center, Veterans Affairs Salt Lake City Healthcare System, Salt Lake City, Utah, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH